ES2136252T3 - Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. - Google Patents

Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.

Info

Publication number
ES2136252T3
ES2136252T3 ES95305594T ES95305594T ES2136252T3 ES 2136252 T3 ES2136252 T3 ES 2136252T3 ES 95305594 T ES95305594 T ES 95305594T ES 95305594 T ES95305594 T ES 95305594T ES 2136252 T3 ES2136252 T3 ES 2136252T3
Authority
ES
Spain
Prior art keywords
acil
diseases caused
treatment
sebacea
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95305594T
Other languages
English (en)
Inventor
James T Mayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2136252T3 publication Critical patent/ES2136252T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UN METODO PARA TRATAR ENFERMEDADES PROVOCADAS POR LOS DESORDENES DE LAS GLANDULAS SEBACEAS, EN HUMANOS Y ANIMALES, QUE COMPRENDE LA ADMINISTRACION A DICHOS HUMANOS Y ANIMALES DE UNA COMPOSICION QUE COMPRENDE UNA CANTIDAD INHIBIDORA DE LA SECRECION DE LAS GLANDULAS SEBACEAS DE UN COMPUESTO ACTIVO QUE COMPRENDE UN INHIBIDOR DE LA TRANSFERASA DE ACILO DE COLESTEROL COA DE ACILO (ACAT) O UNA PRODROGA DEL MISMO. TAMBIEN SE PRESENTA UNA COMPOSICION PARA SU USO EN EL TRATAMIENTO DE LAS ENFERMEDADES PROVOCADAS POR DESORDENES DE LAS GLANDULAS SEBACEAS TALES COMO EL ACNE EN LOS HUMANOS Y EN LOS ANIMALES QUE COMPRENDE UNA CANTIDAD INHIBIDORA DE LA SECRECION DE LAS GLANDULAS SEBACEAS DE UN INHIBIDOR DE LA TRANSFERASA DE ACILO DE COLESTEROL COA DE ACILO (ACAT) O UNA PRODROGA DEL MISMO Y, OPCIONALMENTE, UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.
ES95305594T 1994-08-31 1995-08-10 Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. Expired - Lifetime ES2136252T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/298,735 US6133326A (en) 1994-08-31 1994-08-31 Compositions and methods for decreasing sebum production

Publications (1)

Publication Number Publication Date
ES2136252T3 true ES2136252T3 (es) 1999-11-16

Family

ID=23151816

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95305594T Expired - Lifetime ES2136252T3 (es) 1994-08-31 1995-08-10 Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.

Country Status (9)

Country Link
US (2) US6133326A (es)
EP (1) EP0699439B1 (es)
JP (2) JP3266473B2 (es)
AT (1) ATE185271T1 (es)
CA (1) CA2157142C (es)
DE (1) DE69512589T2 (es)
DK (1) DK0699439T3 (es)
ES (1) ES2136252T3 (es)
GR (1) GR3031917T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU769224B2 (en) * 1998-12-28 2004-01-22 Taisho Pharmaceutical Co., Ltd. External preparation
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
OA12173A (en) 2000-02-02 2006-05-08 Warner Lambert Co Dual inhibitors of cholesterol ester and wax estersynthesis for sebaceous gland disorders.
EP1408902A4 (en) * 2001-06-22 2008-02-13 Millard Marsden Mershon COMPOSITIONS AND METHODS FOR REDUCING LIQUID AND BLOOD LOSS FROM OPEN WOUNDS
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
EP1532974B1 (en) * 2002-03-12 2008-12-17 Galderma Research & Development Composition comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
JP2005060386A (ja) * 2003-07-29 2005-03-10 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP2009102358A (ja) * 2003-07-29 2009-05-14 Rohto Pharmaceut Co Ltd 皮膚外用剤
EP1673077B1 (en) * 2003-10-09 2008-10-01 Warner-Lambert Company LLC Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production
BRPI0614028A2 (pt) * 2005-02-24 2011-03-01 Warner Lambert Co inibidor cristalino de acat
FR2918889B1 (fr) * 2007-07-19 2009-10-23 Galderma Res & Dev Utilisation de l'eflucimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2918890A1 (fr) * 2007-07-19 2009-01-23 Galderma Res & Dev Utilisation du pactimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2920769B1 (fr) 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
FR2920771B1 (fr) * 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de phenylurees, inhibiteurs de l'enzymes soat-1, compositions pharmaceutiques et cosmetiques les contenant
CN101502541B (zh) * 2008-02-04 2011-12-28 成都地奥九泓制药厂 安息香属植物及其提取物的用途
FR2946340B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946342B1 (fr) 2009-06-05 2011-06-24 Galderma Res & Dev Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946346B1 (fr) 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946345B1 (fr) 2009-06-05 2011-05-20 Galderma Res & Dev Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
WO2017214201A1 (en) 2016-06-06 2017-12-14 Thesan Pharmaceuticals, Inc. Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4302456A (en) * 1977-04-13 1981-11-24 The Upjohn Company Process for therapeutic treatment
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
EP0170105B1 (en) 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4751026A (en) 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−（置換フエニルオキシ）−アルカン酸のアリ−ル−およびアラルキルアミド
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US4743605A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
IE61716B1 (en) 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
EP0297610B1 (en) 1987-07-02 1991-03-13 Warner-Lambert Company N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en) 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US5155127A (en) 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) * 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
AU629376B2 (en) 1989-08-04 1992-10-01 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (es) 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
WO1993015058A1 (en) * 1992-01-23 1993-08-05 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
JPH07503737A (ja) * 1992-05-28 1995-04-20 フアイザー・インコーポレイテツド アシル補酵素ａ：コレステロールアシルトランスフェラーゼ（ａｃａｔ）の阻害剤としての新規なｎ−アリールおよびｎ−ヘテロアリール尿素誘導体
US5902805A (en) * 1996-04-22 1999-05-11 L'oreal Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
US9206485B2 (en) 2011-08-19 2015-12-08 J. Edwin Roy Portable sugar mill
US9303539B1 (en) 2012-06-10 2016-04-05 Ags I-Prop, Llc Universal drain plug system and method
US9210886B2 (en) 2014-03-27 2015-12-15 Monsanto Technology Llc Plants and seeds of corn variety CV410274

Also Published As

Publication number Publication date
JP2002053494A (ja) 2002-02-19
DE69512589T2 (de) 2000-01-27
EP0699439A3 (en) 1996-06-26
EP0699439A2 (en) 1996-03-06
US6271268B1 (en) 2001-08-07
CA2157142A1 (en) 1996-03-01
ATE185271T1 (de) 1999-10-15
DK0699439T3 (da) 1999-12-27
JPH0899903A (ja) 1996-04-16
EP0699439B1 (en) 1999-10-06
CA2157142C (en) 1998-06-09
DE69512589D1 (de) 1999-11-11
US6133326A (en) 2000-10-17
JP3266473B2 (ja) 2002-03-18
GR3031917T3 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
ATE401874T1 (de) Verabreichung von capsaicinoiden
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
UY26130A1 (es) Compuestos para tratar la obesidad
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
ES2191192T3 (es) Tienopirimidinas.
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
AR003940A1 (es) Nuevas 1-fenilpirazol-3-carboxamidas substituidas que tienen una gran afinidad por los receptores humanos de la neurotensina, un procedimiento parasu preparacion y composiciones farmaceuticas que las contienen como principios activos.
DK0566405T3 (da) Retinoidholdig vandig geldoseringsform
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
ES2194222T3 (es) Dispositivo para la administracion asistida electricamente de agentes tales como lidocaina y epinefrina.
ES2135429T3 (es) Derivados de ciclohexano sustituidos para el tratamiento de enfermedades.
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
NO20031650D0 (no) Nye legemidler for leversykdommer
CO4230094A1 (es) Composiciones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 699439

Country of ref document: ES